New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT01087554
First seen Jan 19, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This early-phase trial tests a combination of drugs—mTOR inhibitors (sirolimus, everolimus, or temsirolimus) and vorinostat—in people with advanced cancer that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. Up to 249 participants will take part at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mTOR inhibitors (sirolimus, everolimus, temsirolimus) and vorinostat
What this could lead to
If successful, this could point toward a new combination treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not effectiveness. The combination may cause significant side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.